Acutaas Chemicals reported a 70.4% year-on-year increase in net profit after tax (PAT) to ₹74.9 crore for the quarter ended June 30, 2026, driven by robust demand in its Advanced Pharmaceutical Intermediates segment and the commencement of commercial supplies from its new battery chemicals plant. Revenue from operations surged 59.1% to ₹329.7 crore, supported by strong performance in Contract Development and Manufacturing Organization (CDMO) projects and core pharmaceutical products. The company reaffirmed its full-year guidance of 25% revenue growth while maintaining stable margins, despite initial supply chain turbulence caused by geopolitical tensions in the Gulf.

The earnings call, held on July 24, 2026, was moderated by Nuvama Institutional Equities and attended by Chairman and Managing Director Naresh Patel, President of Strategy Abhishek Patel, and Chief Financial Officer Bhavin Shah. The transcript was filed with the BSE and NSE pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Management highlighted that effective supply chain management mitigated raw material pressures, ensuring continuity of operations.

Financial metrics for Q1 FY27 reflect significant margin expansion. Gross profit reached ₹190.9 crore, a 73% increase compared to the same period last year, driving gross margins up by 466 basis points to 57.9%. EBITDA more than doubled to ₹113.1 crore, with margins expanding by 973 basis points to 34.3%. PAT margins improved by 151 basis points to 22.7%. The strong cash position of ₹314 crore provides ample liquidity to fund ongoing expansions without increasing leverage.

Segment Performance

The Advanced Pharmaceutical Intermediates segment remained the primary growth engine, contributing ₹292.7 crore in revenue, a 76.5% year-on-year increase. This growth was driven by both core products and new products gaining volume traction, alongside strong performance in the CDMO business. Conversely, the Specialty Chemicals segment saw revenue decline by 10.6% to ₹37 crore as the company continues to phase out commodity chemicals in favor of higher-margin specialty products. While Battery Fluid Chemicals (BFC) recovered strongly, this was offset by the planned reduction in commodity chemical sales.

Strategic Developments

Management provided updates on key strategic initiatives. The battery chemicals plant has completed trial runs and commenced commercial supply, with production expected to ramp up quarter-on-quarter. The company holds supply contracts for Vinylene Carbonate (VC) and Fluoroethylene Carbonate (FEC), with a total capacity of 4,000 metric tons. Additionally, the Indichem plant for semiconductor chemicals is ahead of schedule, with capital expenditure expected to complete by the end of Q2 FY27. Revenue from this facility is anticipated to begin in FY28.

Capital expenditure for Q1 FY27 totaled ₹56 crore, with ₹41 crore allocated to the ACL site—primarily for the battery chemical project at Jhagadia—and ₹15 crore to the Indichem site. For the full year, management indicated additional capex would be incurred for a new R&D center and land acquisition for future capacity expansion, particularly for the Pharma Intermediate business where existing plants are nearing capacity limits.

What the Numbers Show

The divergence between segment performance highlights Acutaas's strategic shift toward higher-value products. While Specialty Chemicals revenue declined due to the deliberate phase-out of low-margin commodities, the overall company margins expanded significantly. This suggests that the mix shift within the Pharmaceutical Intermediates business—specifically the growing contribution from high-margin CDMO projects—is effectively offsetting the lower-margin impact of emerging businesses like battery chemicals. The strong cash position of ₹314 crore provides ample liquidity to fund these expansions without increasing leverage.

Acutaas Chemicals reported a consolidated net profit of ₹750 million for the first quarter ended June 30, 2026, marking a 70.4% year-on-year increase from ₹440 million in the corresponding period of FY26. The speciality chemicals manufacturer’s revenue from operations rose 59.1% to ₹3,297 million, driven by higher volumes in its pharma intermediates segment and improved operational efficiency. Profit after tax (PAT) margins expanded to 22.7% from 21.2% last year, reflecting strong operating leverage despite a decline in other income. This performance underscores the company’s ability to scale profitability through margin expansion rather than just volume growth.

The Board of Directors approved the unaudited standalone and consolidated financial results during a meeting held on July 24, 2026. The results were reviewed by the Audit Committee and subjected to a limited review by statutory auditors M/s Maheshwari & Co., Chartered Accountants. The company disclosed compliance with Regulation 33 and Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. An accompanying investor presentation was filed with the Bombay Stock Exchange and National Stock Exchange of India Limited.

Financial Performance Highlights

Consolidated revenue from operations stood at ₹3,297 million in Q1FY27, compared to ₹2,072 million in Q1FY26. Gross profit surged 73.0% to ₹1,909 million, pushing gross margins up by 466 basis points to 57.9%. EBITDA more than doubled to ₹1,131 million from ₹509 million, with EBITDA margins improving to 34.3% from 24.6%. Total income reached ₹3,314.76 million.

On a standalone basis, Acutaas Chemicals reported a net profit of ₹759 million, up 70.2% from ₹446.5 million in Q1FY26. Standalone revenue from operations grew 56.5% to ₹3,224.1 million. Earnings per share (basic) increased to ₹9.07 on a consolidated basis and ₹9.27 on a standalone basis, compared to ₹5.41 and ₹5.45 respectively in the previous year’s quarter.

Segmental Revenue Breakdown

The growth was primarily fueled by the Advance Intermediates segment, which saw revenue jump 76.5% to ₹2,927 million from ₹1,658 million in Q1FY26. In contrast, the Specialty Chemicals segment experienced a decline of 10.6%, with revenue falling to ₹370 million from ₹414 million. Naresh Patel, Executive Chairman & Managing Director, attributed the overall growth to the agility of the business model and strong demand in contract development and manufacturing organization (CDMO) services.

Operational Developments and Certifications

During the quarter, Acutaas Chemicals Electrolytes Private Limited (ACEPL), a subsidiary, issued equity shares on a partly paid-up basis to A.R.Z Pharma Ltd. This transaction diluted the parent company’s stake in ACEPL from 100% to 90%, effective May 19, 2026. ACEPL remains a subsidiary, with no change in control reported by management.

Additionally, the Central Goods & Service Tax and Central Excise (CGST & CE), Anti-Evasion Department, conducted inspection and search proceedings at the company’s registered office and manufacturing facility in Surat, Gujarat, on June 22–23, 2026. Management stated that based on information available as of the board meeting date, they do not expect any material impact on the financial position or results of operations.

The company also announced it has been certified as a Great Place to Work and received the Responsible Care certification from the Indian Chemical Council, reaffirming its commitment to safety, health, and environmental performance standards.

What the Numbers Show

The divergence between revenue growth (59%) and expense growth highlights improved operating leverage for Acutaas Chemicals in Q1FY27. While other income dropped sharply due to lower interest income and foreign exchange gains, the core operating profit expanded disproportionately, indicating stronger pricing power or cost containment in its speciality chemicals business. The dilution in ACEPL introduces a non-controlling interest component but does not alter strategic control, suggesting a partnership model aimed at scaling electrolyte production capabilities without full capital outlay. Naresh Patel expressed confidence in delivering 25% revenue growth for the full year with stable margins.